title: Inflammatory mediators of cerebrospinal fluid from patients with spinal cord injury.
abstract: BACKGROUND
  The guidelines of MP treatment for acute SCI are still under debate. We examined the inflammatory mediators of CSF in patients with SCI and assessed the effect of MP treatment.
  
  
  METHODS
  We studied 7 patients with acute SCI at the cervical level and examined the mediators of CSF in patients by cytokine antibody array, ELISA and gelatin zymography.
  
  
  RESULTS
  We found that levels of IL-6, IL-8, monocyte chemoattractant protein-1, neutrophil-activating peptide 2, intracellular adhesion molecule-1, soluble Fas, tissue inhibitors of metalloproteinase 1, and matrix metalloproteinases-2 and -9 were upregulated in patients with complete SCI without MP treatment as compared to patients with MP treatments, incomplete SCI, or controls. Nerve growth factor was upregulated in patients with MP treatment.
  
  
  CONCLUSIONS
  We suggest that a neuroinflammatory CSF profile after complete SCI could be suppressed with MP treatment via downregulating the expression of various cytokines.
authors.affiliation: Department of Neurosurgery, Shin Kong Wu Ho-Su Memorial Hospital, and Graduate Institute of Cell and Molecular Biology, Taipei Medical University, Taipei 111, Taiwan.
authors.forename: Ming-Cheng
authors.initials: MC
authors.lastname: Tsai
authors.forename: Chih-Peng
authors.initials: CP
authors.lastname: Wei
authors.forename: Dan-Yang
authors.initials: DY
authors.lastname: Lee
authors.forename: Yi-Tzu
authors.initials: YT
authors.lastname: Tseng
authors.forename: Ming-Dar
authors.initials: MD
authors.lastname: Tsai
authors.forename: Yung-Luen
authors.initials: YL
authors.lastname: Shih
authors.forename: Yi-Hsuan
authors.initials: YH
authors.lastname: Lee
authors.forename: Shwu-Fen
authors.initials: SF
authors.lastname: Chang
authors.forename: Sy-Jye
authors.initials: SJ
authors.lastname: Leu
mesh_terms: D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D016207:Cytokines / Q000134:cerebrospinal fluid; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D018836:Inflammation Mediators / Q000134:cerebrospinal fluid*; D008297:Male; D020782:Matrix Metalloproteinases / Q000134:cerebrospinal fluid; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009414:Nerve Growth Factors / Q000096:biosynthesis / Q000235:genetics; D019635:Neurosurgical Procedures; D013119:Spinal Cord Injuries / Q000134:cerebrospinal fluid* / Q000188:drug therapy / Q000601:surgery; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D016207:Cytokines; D018836:Inflammation Mediators; D009414:Nerve Growth Factors; D020782:Matrix Metalloproteinases; D008775:Methylprednisolone